Forte Biosciences, Inc. - 8-K Filing
Forte Biosciences stockholders approved an amended and restated 2021 Equity Incentive Plan, increasing the share reserve by 5,190,000 shares (including 3,340,000 from a prior approval in January 2025). The plan aims to attract personnel through stock options, restricted stock units, and performance awards. At its May 29 annual meeting, the company also elected three Class III directors: Steven Kornfeld, Scott Brun, M.D., and Paul A. Wagner, Ph.D. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 below), the Company’s stockholders approved the further amendment and restatement of the 2021 Equity Incentive Plan (as currently amended and, 9.01 Financial Statements and Exhibits)
Tickers: $FBRX